Partnership Opportunities

Progenra seeks industry partners to execute mutually beneficial licensing agreements for the company's early stage assets and/or the UbiPro™ Drug Discovery Platform. Progenra wishes to continue to work with academic institutions to further dissect the ubiquitin pathway. We also seek discussions on in-licensing from both commercial and academic institutions' technologies and/or compounds that are complementary to Progenra's internal development strategy.

Progenra’s business development team has worked successfully with a variety of companies and academic institutions to establish agreements that fit within our partner’s strategic focus and goals. Our expert discovery team and external network is capable of ensuring solutions to any problem.

Partnering with Progenra Includes:

  • Unparalleled expertise in the Ubiquitin Proteasome pathway
  • Access to all the tools and technology under Progenra's UbiPro™ Drug Discovery Platform on an exclusive or nonexclusive basis to identify and develop a modifier of a deubiquitylase or ligase for use as a therapeutic
  • Research and early preclinical development work to assist in the identification and development of a proposed therapeutic, including counterscreening and selectivity screening
  • Development of new targets within the ubiquitin-proteasome pathway for the identification of modifiers

Research collaborations with Progenra allow our partners to overcome the greatest barriers to working in the ubiquitin field.

Please contact the Progenra Business Development Team for inquiries: bd@progenra.com